Background. Acinetobacter baumannii is an aerobic coccobacillus, non-motile, non-capsulated, negative-oxidizing, and positive catalase Gram negative bacteria. This bacteria is known as the main pathogen causing nosocomial disease. Other bacteria that are also pathogens of nosocomial disease are Klebsiella pneumonia and Pseudomonas aeruginosa. Another worth noticing is A. baumanii, a bacteria that is resistant against varying antibiotics, like cephalosporin, carbapenem (imipenem or meropenem), sulbactam, fluoroquinolone, and aminoglycoside (tobramycine or amikacin).
Objective. To know the effectiveness of Colistin – Tigecycline Combination Therapy toward clinical parameter transition (blood leukocyte, sputum leukocyte, C-reactive protein, procalcitonin, body temperature, lactate, and survival) of Acinetobacter baumanii- related pneumonia patients.
Methodology. Research was conducted using retrospective cohort (observational) method using medical records of Royal Taruma Hospital patients who underwent surgery between 2011-2015 using analytical descriptive technique.
Result. Colistin – Tigecycline Combination Therapy does not have any significant effect on the clinical parameter transition on Acinetobacter baumanii- related pneumonia patients. The result gained through study on blood leukocyte, basophil, eosinophil, neutrophil, lymphocyte, CRP, PCT, and lactate pre and post-treatment does not show any significant change. Meanwhile, there is an evidence of positive effect on monocyte and body temperature as shown by the decrease after treatment using Colistin – Tigecycline Combination Therapy.
Conclusion. Overall, Colistin – Tigecycline Combination Therapy does not have any positive effect on the clinical parameter transition on Acinetobacter baumanii- related pneumonia patients, except body temperature and monocyte. |